Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Deciphera Pharmaceuticals stock price, quote, forecast and news

DCPH
US24344T1016
A2H48H

Price

25.59
Today +/-
+0
Today %
+0 %
P

Deciphera Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Deciphera Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Deciphera Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Deciphera Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Deciphera Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Deciphera Pharmaceuticals Stock Price History

DateDeciphera Pharmaceuticals Price
6/11/202425.59 undefined
6/10/202425.59 undefined

Deciphera Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Deciphera Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Deciphera Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Deciphera Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Deciphera Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Deciphera Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Deciphera Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Deciphera Pharmaceuticals’s growth potential.

Deciphera Pharmaceuticals Revenue, EBIT and net profit per share

DateDeciphera Pharmaceuticals RevenueDeciphera Pharmaceuticals EBITDeciphera Pharmaceuticals Net Income
2029e610.88 M undefined0 undefined136.72 M undefined
2028e509.33 M undefined53.93 M undefined61.09 M undefined
2027e434.31 M undefined-25.1 M undefined-38.59 M undefined
2026e382.46 M undefined-73.21 M undefined-50.66 M undefined
2025e264.6 M undefined-168.31 M undefined-137.12 M undefined
2024e205.66 M undefined-203.21 M undefined-187.97 M undefined
2023163.36 M undefined-210.96 M undefined-194.94 M undefined
2022134.04 M undefined-182.72 M undefined-178.93 M undefined
202196.15 M undefined-300.08 M undefined-299.96 M undefined
202042.09 M undefined-271.19 M undefined-266.49 M undefined
201925 M undefined-200.73 M undefined-192.26 M undefined
20180 undefined-104.1 M undefined-99.85 M undefined
20170 undefined-50.94 M undefined-50.28 M undefined
20160 undefined-25.84 M undefined-25.94 M undefined
20150 undefined-17.61 M undefined-19.82 M undefined

Deciphera Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000254296134163205264382434509610
-----68.00128.5739.5821.6425.7728.7844.7013.6117.2819.84
-----97.6296.8893.2897.55------
000004193125159000000
-17-25-50-104-200-271-300-182-210-203-168-73-25530
-----800.00-645.24-312.50-135.82-128.83-99.02-63.64-19.11-5.7610.41-
-19-25-50-99-192-266-299-178-194-187-137-50-3861136
-31.58100.0098.0093.9438.5412.41-40.478.99-3.61-26.74-63.50-24.00-260.53122.95
30.6830.6830.6835.3942.8755.7858.0875.585.06000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Deciphera Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Deciphera Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
25.7857.46196.75293.76579.58551.93285.63324.49306.22
0000013.920.622.4331.95
000000000
000005.7214.1320.5621.21
0.610.791.437.2713.8312.4918.6625.4821.72
26.3858.25198.18301.04593.41584.03339.01392.96381.1
0.390.510.8413.4527.4945.9245.4143.2537.49
000009.3841.9514.5546.7
000000000
000000000
000000000
0.020.180.081.071.513.13.113.288.28
0.410.690.9114.522958.490.4761.0892.47
26.7958.94199.1315.56622.41642.43429.48454.04473.57
                 
137.37192.670.330.380.520.580.590.680.81
00.010.380.581.031.31.361.581.78
-119.65-145.59-195.87-295.72-487.98-754.47-1,054.43-1,233.36-1,428.31
0000011151-983577
0000111-100000
22.0652.91183.97279.98546.47543.68304.72341.69350.92
1.61.414.48.3119.5812.3113.1318.6126.48
1.262.969.2314.2540.4654.354.1350.6147.73
000003.3829.5117.2526.07
000000000
18718718718700000
3.054.5613.8222.7460.0469.9996.7786.47100.28
1.681.481.291.1100000
000000000
000.0111.7315.928.7627.9925.8822.38
1.681.481.3112.8315.928.7627.9925.8822.38
4.736.0415.1235.5875.9498.76124.76112.35122.65
26.7958.94199.1315.56622.41642.43429.48454.04473.57
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Deciphera Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Deciphera Pharmaceuticals's financial health and stability.

Assets

Deciphera Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Deciphera Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Deciphera Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Deciphera Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-19-25-50-99-192-266-299-178-194
000002322
000000000
118324-130-32-1
72919377510110698
000000000
000000000
-13-23-36-86-149-239-240-152-146
000-1-4-5-500
000-2-46028176-3412
000-1-45533182-3313
000000000
7000-10000
315518118643822714165152
385417618543622614164152
---4.00------
000000000
253113997-17315-48-2218
-13.41-23.31-37.11-87.91-154.23-245-246.79-153.7-147.48
000000000

Deciphera Pharmaceuticals stock margins

The Deciphera Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Deciphera Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Deciphera Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Deciphera Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Deciphera Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Deciphera Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Deciphera Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Deciphera Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Deciphera Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Deciphera Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Deciphera Pharmaceuticals Margin History

Deciphera Pharmaceuticals Gross marginDeciphera Pharmaceuticals Profit marginDeciphera Pharmaceuticals EBIT marginDeciphera Pharmaceuticals Profit margin
2029e97.72 %0 %22.38 %
2028e97.72 %10.59 %11.99 %
2027e97.72 %-5.78 %-8.89 %
2026e97.72 %-19.14 %-13.25 %
2025e97.72 %-63.61 %-51.82 %
2024e97.72 %-98.81 %-91.4 %
202397.72 %-129.14 %-119.34 %
202293.46 %-136.32 %-133.49 %
202196.95 %-312.1 %-311.98 %
202099.47 %-644.36 %-633.19 %
201997.72 %-802.9 %-769.02 %
201897.72 %0 %0 %
201797.72 %0 %0 %
201697.72 %0 %0 %
201597.72 %0 %0 %

Deciphera Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Deciphera Pharmaceuticals earnings per share therefore indicates how much revenue Deciphera Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Deciphera Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Deciphera Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Deciphera Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Deciphera Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Deciphera Pharmaceuticals Revenue, EBIT and net profit per share

DateDeciphera Pharmaceuticals Sales per ShareDeciphera Pharmaceuticals EBIT per shareDeciphera Pharmaceuticals Earnings per Share
2029e7.06 undefined0 undefined1.58 undefined
2028e5.89 undefined0 undefined0.71 undefined
2027e5.02 undefined0 undefined-0.45 undefined
2026e4.42 undefined0 undefined-0.59 undefined
2025e3.06 undefined0 undefined-1.59 undefined
2024e2.38 undefined0 undefined-2.17 undefined
20231.92 undefined-2.48 undefined-2.29 undefined
20221.78 undefined-2.42 undefined-2.37 undefined
20211.66 undefined-5.17 undefined-5.16 undefined
20200.75 undefined-4.86 undefined-4.78 undefined
20190.58 undefined-4.68 undefined-4.48 undefined
20180 undefined-2.94 undefined-2.82 undefined
20170 undefined-1.66 undefined-1.64 undefined
20160 undefined-0.84 undefined-0.85 undefined
20150 undefined-0.57 undefined-0.65 undefined

Deciphera Pharmaceuticals business model

Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Deciphera Pharmaceuticals SWOT Analysis

Strengths

Deciphera Pharmaceuticals Inc has a strong portfolio of innovative cancer therapeutics, developed through extensive research and clinical trials.

The company benefits from a highly skilled and experienced management team, with deep expertise in the biopharmaceutical industry.

Deciphera Pharmaceuticals Inc has secured strong financial backing, allowing it to invest in research and development initiatives.

Weaknesses

As a relatively small biopharmaceutical company, Deciphera Pharmaceuticals Inc may face challenges in competing with larger, more established players in the industry.

The company's success heavily relies on the successful development and regulatory approval of its pipeline products, which may involve considerable time and investment.

Deciphera Pharmaceuticals Inc operates in a highly regulated industry, subject to strict compliance requirements and potential delays in product commercialization.

Opportunities

The rising global prevalence of cancer presents a significant market opportunity for Deciphera Pharmaceuticals Inc to address with its innovative therapies.

Expanding partnerships and collaborations with research institutions and biopharmaceutical companies can further enhance Deciphera Pharmaceuticals Inc's research capabilities and broaden its product pipeline.

The continuous advancements in precision medicine and targeted therapies offer potential for Deciphera Pharmaceuticals Inc to develop personalized treatment options.

Threats

Deciphera Pharmaceuticals Inc faces intense competition from both established pharmaceutical companies and emerging biotechnology firms with similar drug candidates.

The ever-evolving regulatory landscape and potential changes in healthcare policies may impact the company's ability to successfully navigate the drug development and commercialization process.

Disruptions to the global supply chain, such as those caused by the COVID-19 pandemic, can adversely affect Deciphera Pharmaceuticals Inc's operations and ability to meet demand.

Deciphera Pharmaceuticals Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Deciphera Pharmaceuticals Revenue by Segment

Segmente2023202220212020
Product Revenues, net159.07 M USD14.3 M USD87.39 M USD-
Collaboration Arrangement4.28 M USD12 M USD12 M USD400,000 USD
Product---1.5 M USD

Deciphera Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Deciphera Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Deciphera Pharmaceuticals shares outstanding

The number of shares was Deciphera Pharmaceuticals in 2023 — This indicates how many shares 85.06 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Deciphera Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Deciphera Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Deciphera Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Deciphera Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.57 -0.52  (8.03 %)2024 Q1
12/31/2023-0.59 -0.54  (8.8 %)2023 Q4
9/30/2023-0.62 -0.58  (6.6 %)2023 Q3
6/30/2023-0.63 -0.57  (9.87 %)2023 Q2
3/31/2023-0.61 -0.6  (0.83 %)2023 Q1
12/31/2022-0.57 -0.6  (-5.5 %)2022 Q4
9/30/2022-0.59 -0.55  (6.45 %)2022 Q3
6/30/2022-0.67 -0.6  (10.61 %)2022 Q2
3/31/2022-0.92 -0.8  (12.94 %)2022 Q1
12/31/2021-1.41 -1.51  (-7.34 %)2021 Q4
1
2
3

Eulerpool ESG Scorecard© for the Deciphera Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

35

👫 Social

89

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees18
Share of Asian management—
Percentage of Hispanic/Latino employees3
Hispano/Latino Management share—
Percentage of Black employees2
Black Management Share—
Percentage of white employees71
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Deciphera Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
6.69290 % Deerfield Management Company, L.P.5,788,024-1,109,58212/31/2023
6.01295 % Armistice Capital LLC5,200,000588,00012/31/2023
5.55220 % Redmile Group, LLC4,801,540326,15612/31/2023
5.53346 % BlackRock Institutional Trust Company, N.A.4,785,332483,31712/31/2023
5.08135 % The Vanguard Group, Inc.4,394,35438,65412/31/2023
27.72168 % Brightstar Associates LLC23,973,709914,0012/7/2024
2.85709 % State Street Global Advisors (US)2,470,813159,69512/31/2023
2.13922 % Polar Capital LLP1,850,000100,00012/31/2023
2.10152 % Goldman Sachs & Company, Inc.1,817,391389,95712/31/2023
1.90336 % Morgan Stanley & Co. LLC1,646,030443,10412/31/2023
1
2
3
4
5
...
10

Deciphera Pharmaceuticals Executives and Management Board

Mr. Steven Hoerter52
Deciphera Pharmaceuticals President, Chief Executive Officer, Director (since 2018)
Compensation 3.55 M
Dr. Matthew Sherman67
Deciphera Pharmaceuticals Executive Vice President, Chief Medical Officer
Compensation 1.49 M
Mr. Thomas Kelly52
Deciphera Pharmaceuticals Chief Financial Officer, Executive Vice President, Treasurer
Compensation 1.41 M
Mr. Daniel Flynn69
Deciphera Pharmaceuticals Founder, Executive Vice President, Chief Scientific Officer (since 2003)
Compensation 1.39 M
Mr. Daniel Martin48
Deciphera Pharmaceuticals Senior Vice President, Chief Commercial Officer
Compensation 1.13 M
1
2
3
4

Deciphera Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Zai Lab Stock
Zai Lab
SupplierCustomer0,640,10-0,29-0,270,88-
Omnicom Stock
Omnicom
SupplierCustomer0,07--0,26-0,10-0,21-0,65
Sprint Bioscience Stock
Sprint Bioscience
SupplierCustomer-0,370,40-0,25-0,280,670,81
1

Most common questions regarding Deciphera Pharmaceuticals

What values and corporate philosophy does Deciphera Pharmaceuticals represent?

Deciphera Pharmaceuticals Inc represents a strong commitment to improving patients' lives through innovative oncology treatments. Guided by a patient-centric approach, the company focuses on personalized medicine that targets specific cancer signaling pathways. Deciphera Pharmaceuticals Inc believes in advancing precision oncology therapies to address unmet medical needs and strives to make a significant impact in the field of cancer research. With their dedicated team and cutting-edge research, Deciphera Pharmaceuticals Inc is devoted to developing transformative therapies that provide hope and enhance the quality of life for patients with cancer.

In which countries and regions is Deciphera Pharmaceuticals primarily present?

Deciphera Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Deciphera Pharmaceuticals achieved?

Deciphera Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained regulatory approval for their lead kinase inhibitor, Qinlock® (ripretinib), to treat advanced gastrointestinal stromal tumors (GIST). Deciphera Pharmaceuticals also obtained accelerated approval from the U.S. FDA for Qinlock® as a fourth-line therapy for GIST patients. Furthermore, they received breakthrough therapy designation from the FDA for Qinlock® in the second-line GIST treatment setting. These milestones highlight Deciphera Pharmaceuticals' commitment to developing innovative treatments for rare cancers and their dedication to advancing patient care.

What is the history and background of the company Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals Inc. is a renowned biopharmaceutical company, known for its innovative approach in developing kinase inhibitor therapies to improve the lives of patients. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera has made significant advancements in precision medicine by targeting the underlying causes of cancer and other diseases. With a focus on kinase switch control inhibitors (KSCIs), the company strives to provide effective treatment options for patients with various types of cancers and other serious diseases. Deciphera's dedication to research and development has led to the discovery of multiple potential drug candidates, establishing them as a key player in the pharmaceutical industry.

Who are the main competitors of Deciphera Pharmaceuticals in the market?

Deciphera Pharmaceuticals Inc faces competition from several players in the market. Some of its main competitors include Blueprint Medicines Corporation, Array BioPharma Inc, and Loxo Oncology Inc. These companies are also engaged in the research and development of innovative therapies and treatments in the pharmaceutical industry. However, Deciphera Pharmaceuticals distinguishes itself through its unique approach and expertise in developing highly targeted precision medicine solutions. With its strong pipeline and advancements in kinase inhibitor drugs, Deciphera Pharmaceuticals Inc aims to stand out as a leading player in the market.

In which industries is Deciphera Pharmaceuticals primarily active?

Deciphera Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Deciphera Pharmaceuticals?

The business model of Deciphera Pharmaceuticals Inc revolves around developing and commercializing targeted therapeutics for the treatment of cancer. With a primary focus on kinase inhibitors, Deciphera Pharmaceuticals aims to address unmet medical needs and improve patient outcomes. The company prioritizes the discovery and development of small molecule drugs, leveraging its proprietary Kinase Switch Control Inhibitor Platform. By combining innovative science, strategic partnerships, and rigorous clinical research, Deciphera Pharmaceuticals aims to bring transformational therapies to patients living with cancer.

What is the P/E ratio of Deciphera Pharmaceuticals 2024?

The Deciphera Pharmaceuticals P/E ratio is -11.58.

What is the P/S ratio of Deciphera Pharmaceuticals 2024?

The Deciphera Pharmaceuticals P/S ratio is 10.58.

What is the AlleAktien quality score of Deciphera Pharmaceuticals?

The AlleAktien quality score for Deciphera Pharmaceuticals is 3/10.

What is the revenue of Deciphera Pharmaceuticals 2024?

The expected Deciphera Pharmaceuticals revenue is 205.66 M USD.

How high is the profit of Deciphera Pharmaceuticals 2024?

The expected Deciphera Pharmaceuticals profit is -187.97 M USD.

What is the business model of Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative drugs for the treatment of cancer. The company operates in three main areas: clinical development, research and development, and marketing. The clinical development division focuses on developing drugs for the treatment of cancer. The research and development division specializes in discovering new drugs for cancer treatment. The marketing division works closely with partners to market the company's medical innovations worldwide. The company's goal is to improve the lives of cancer patients and extend their survival through the development and marketing of effective drugs. Overall, Deciphera Pharmaceuticals is committed to improving the lives of cancer patients globally.

What is the Deciphera Pharmaceuticals dividend?

Deciphera Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Deciphera Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Deciphera Pharmaceuticals or the company does not pay out a dividend.

What is the Deciphera Pharmaceuticals ISIN?

The ISIN of Deciphera Pharmaceuticals is US24344T1016.

What is the Deciphera Pharmaceuticals WKN?

The WKN of Deciphera Pharmaceuticals is A2H48H.

What is the Deciphera Pharmaceuticals ticker?

The ticker of Deciphera Pharmaceuticals is DCPH.

How much dividend does Deciphera Pharmaceuticals pay?

Over the past 12 months, Deciphera Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Deciphera Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Deciphera Pharmaceuticals?

The current dividend yield of Deciphera Pharmaceuticals is .

When does Deciphera Pharmaceuticals pay dividends?

Deciphera Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Deciphera Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Deciphera Pharmaceuticals located?

Deciphera Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Deciphera Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Deciphera Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Deciphera Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Deciphera Pharmaceuticals in the year 2023?

In the year 2023, Deciphera Pharmaceuticals distributed 0 USD as dividends.

In which currency does Deciphera Pharmaceuticals pay out the dividend?

The dividends of Deciphera Pharmaceuticals are distributed in USD.

All fundamentals about Deciphera Pharmaceuticals

Our stock analysis for Deciphera Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.